TY - JOUR
T1 - High prevalence of serum anti-NH2-terminal of α-enolase antibodies in patients with multiple system atrophy and corticobasal syndrome
AU - Kikuchi, Akio
AU - Yoneda, Makoto
AU - Hasegawa, Takafumi
AU - Matsunaga, Akiko
AU - Ikawa, Masamichi
AU - Nakamura, Takaaki
AU - Ezura, Michinori
AU - Baba, Toru
AU - Sugeno, Naoto
AU - Ishiyama, Shun
AU - Nakamoto, Yasunari
AU - Takeda, Atsushi
AU - Aoki, Masashi
N1 - Funding Information:
This study was supported in part by a Grant for “the Research Committee for Ataxic Diseases” of the Research on Measures for Intractable Diseases from the Ministry of Health, Labour and Welfare, Japan, and Grants-in-Aid for Scientific Research (C) (20K07923) from the Japan Society for the Promotion of Science, Japan.
Publisher Copyright:
© 2021, Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2021/11
Y1 - 2021/11
N2 - Background: Hashimoto’s encephalopathy with serum anti-NH2-terminal of α-enolase (NAE) antibodies occasionally displays clinical symptoms such as cerebellar ataxia and parkinsonism. We studied the frequency of anti-NAE antibodies in patients with Parkinson-plus syndrome. Methods: We examined the positive rates of anti-NAE antibodies in 47 patients with multiple system atrophy (MSA), 29 patients with Parkinson’s disease (PD), eight patients with corticobasal syndrome (CBS), and 18 patients with progressive supranuclear palsy (PSP) using conventional immunoblot analysis. Results: Positive anti-NAE antibody rates of 31.9%, 10.3%, 50.0%, and 11.1% were reported in the MSA, PD, CBS, and PSP patients, respectively. The duration from onset to a wheelchair-bound state in seropositive MSA patients tended to be shorter than that in seronegative MSA patients. Conclusions: Anti-NAE antibodies are detected in some patients clinically diagnosed with MSA and CBS. Although its pathophysiological significance remains uncertain, serum anti-NAE antibodies might represent a prognostic marker in the clinical course of MSA.
AB - Background: Hashimoto’s encephalopathy with serum anti-NH2-terminal of α-enolase (NAE) antibodies occasionally displays clinical symptoms such as cerebellar ataxia and parkinsonism. We studied the frequency of anti-NAE antibodies in patients with Parkinson-plus syndrome. Methods: We examined the positive rates of anti-NAE antibodies in 47 patients with multiple system atrophy (MSA), 29 patients with Parkinson’s disease (PD), eight patients with corticobasal syndrome (CBS), and 18 patients with progressive supranuclear palsy (PSP) using conventional immunoblot analysis. Results: Positive anti-NAE antibody rates of 31.9%, 10.3%, 50.0%, and 11.1% were reported in the MSA, PD, CBS, and PSP patients, respectively. The duration from onset to a wheelchair-bound state in seropositive MSA patients tended to be shorter than that in seronegative MSA patients. Conclusions: Anti-NAE antibodies are detected in some patients clinically diagnosed with MSA and CBS. Although its pathophysiological significance remains uncertain, serum anti-NAE antibodies might represent a prognostic marker in the clinical course of MSA.
KW - Anti-NH-terminal of α-enolase antibodies
KW - Corticobasal syndrome
KW - Multiple system atrophy
KW - Parkinson’s disease
KW - Progressive supranuclear palsy
UR - http://www.scopus.com/inward/record.url?scp=85104738002&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104738002&partnerID=8YFLogxK
U2 - 10.1007/s00415-021-10553-2
DO - 10.1007/s00415-021-10553-2
M3 - Article
C2 - 33856546
AN - SCOPUS:85104738002
VL - 268
SP - 4291
EP - 4295
JO - Deutsche Zeitschrift fur Nervenheilkunde
JF - Deutsche Zeitschrift fur Nervenheilkunde
SN - 0340-5354
IS - 11
ER -